Resources Repository
-
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Test Performance | Costing Methods | Government/Law | North America | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Costing Methods | Government/Law | North America | Chronic Disease/Risk | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Costing Methods | Government/Law | North America | Chronic Disease/Risk | Preferences/Values | Benefit-Cost Analysis | Mental Health | Policy/Regulation | Economics/Finance | Health/Medicine -
Online LearningVideo, Teaching Resource 2017Forum. The Opioid Crisis: A Governors Roundtable
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for …
Opioid overdoses claim the lives of 91 Americans every day, according to the Centers for Disease Control and Prevention. This Forum - The Opioid Crisis: A Governors Roundtable, is part of the series, Policy Controversies, and was presented jointly with PRI’s The World & WGBH News. In this multimedia forum, four former governors offered candid insights into how government policy can help, exploring what works and what doesn’t. They spoke about experiences within their own…
Priority Setting/Ethics | Government/Law | North America | Chronic Disease/Risk | Health Outcomes | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Costing Methods | Government/Law | North America | Chronic Disease/Risk | Benefit-Cost Analysis | Policy/Regulation | Health/Medicine -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | Government/Law | North America | Chronic Disease/Risk | Preferences/Values | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Mental Health | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Europe -
Lesson/ModuleWeb Portal, Teaching Resource 2016Placing a Bet: New Therapy for Parkinson's Disease
This module is intended for use by business school students. It examines the decision-making process …
This module is intended for use by business school students. It examines the decision-making process at a pharmaceutical company as its chief operating officer decides whether to invest in the development and licensing of a promising treatment for Parkinson’s disease. The module is structured around a drug development case that provides students with opportunities to: (1) analyze a rich and realistic description of the complex scientific and medical results associated with a promising therapeutic molecule…
Test Performance | Government/Law | North America | Chronic Disease/Risk | Technology Assessment | Policy/Regulation | Business/Industry | Health/Medicine | Science/Technology | Global | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Government/Law | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine